We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna's (MRNA) Coronavirus Vaccine Study Begins in Japan
Read MoreHide Full Article
Moderna Inc.’s (MRNA - Free Report) partner Takeda Pharmaceutical announced that it has dosed the first participant in a phase I/II study with Moderna’s mRNA-based COVID-19 vaccine candidate, mRNA-1273, in Japan. The study is being led by Japan’s Takeda whose development code for the COVID-19 vaccine candidate is TAK-919.
The placebo-controlled phase I/II study will enroll 200 participants aged 20 years and above in Japan. The study will evaluate the safety and immunogenicity of two shots of mRNA-1273 administered at an interval of 28 days.
Notably, upon potential licensure in Japan, per an agreement, Takeda will import and distribute 50 million doses of mRNA-1273, starting in the first half of 2021.
Shares of Moderna have skyrocketed 519.4% in the past year compared with the industry’s increase of 14.9%.
We note that Moderna tasted a major success when it received approval for emergency use of mRNA-1273 — its sole commercial product, in December last year, in the United States. This was followed by a similar authorization in Canada, Europe, the United Kingdom, Israel and Switzerland. The vaccine is under review in other countries.
Notably, Moderna started development of mRNA-1273 in the beginning of 2020, following the coronavirus outbreak. The vaccine candidate achieved a 94.1% efficacy rate in pivotal late-stage study.
Several millions of doses of the vaccine candidate have already been administered in the United States. The company is expected to generate billions in revenues in 2021 from the sales of its coronavirus vaccine.
Meanwhile, Pfizer (PFE - Free Report) and its partner Germany-based BioNTech’s (BNTX - Free Report) mRNA-based COVID-19 vaccine, BNT162b2, is also approved for emergency/temporary/conditional use in more than 40 countries, including the United States and 27 EU member countries.
AstraZeneca’s (AZN - Free Report) adenovirus-based coronavirus vaccine candidate, AZD1222, is approved for emergency use in the United Kingdom and India.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Bigstock
Moderna's (MRNA) Coronavirus Vaccine Study Begins in Japan
Moderna Inc.’s (MRNA - Free Report) partner Takeda Pharmaceutical announced that it has dosed the first participant in a phase I/II study with Moderna’s mRNA-based COVID-19 vaccine candidate, mRNA-1273, in Japan. The study is being led by Japan’s Takeda whose development code for the COVID-19 vaccine candidate is TAK-919.
The placebo-controlled phase I/II study will enroll 200 participants aged 20 years and above in Japan. The study will evaluate the safety and immunogenicity of two shots of mRNA-1273 administered at an interval of 28 days.
Notably, upon potential licensure in Japan, per an agreement, Takeda will import and distribute 50 million doses of mRNA-1273, starting in the first half of 2021.
Shares of Moderna have skyrocketed 519.4% in the past year compared with the industry’s increase of 14.9%.
We note that Moderna tasted a major success when it received approval for emergency use of mRNA-1273 — its sole commercial product, in December last year, in the United States. This was followed by a similar authorization in Canada, Europe, the United Kingdom, Israel and Switzerland. The vaccine is under review in other countries.
Notably, Moderna started development of mRNA-1273 in the beginning of 2020, following the coronavirus outbreak. The vaccine candidate achieved a 94.1% efficacy rate in pivotal late-stage study.
Several millions of doses of the vaccine candidate have already been administered in the United States. The company is expected to generate billions in revenues in 2021 from the sales of its coronavirus vaccine.
Meanwhile, Pfizer (PFE - Free Report) and its partner Germany-based BioNTech’s (BNTX - Free Report) mRNA-based COVID-19 vaccine, BNT162b2, is also approved for emergency/temporary/conditional use in more than 40 countries, including the United States and 27 EU member countries.
AstraZeneca’s (AZN - Free Report) adenovirus-based coronavirus vaccine candidate, AZD1222, is approved for emergency use in the United Kingdom and India.
Zacks Rank
Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>